2026 Interim report
Filed with HKEX · Stock code 6990 · · 114 pages · English
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. on 6ix
Earlier from Sichuan Kelun-Biotech Biopharmaceutical
- Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
- Kelun-Biotech Announces 2026 Interim Results
- NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
- Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
- Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma
Later from Sichuan Kelun-Biotech Biopharmaceutical
- Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Sichuan Kelun-Biotech Biopharmaceutical into a list and get an email when it puts out news.
Follow Sichuan Kelun-Biotech Biopharmaceutical